| Nasdaq: OXGN
Oxigene, Inc. engages in the development of therapeutics to treat cancer and eye diseases. It offers anti-vascular drugs referred to as vascular disrupting agents. Its products include Zybrestat (fosbretabulin) and Zybrestat Topical. The company was founded in 1988 and is headquartered in South San Francisco, CA.